-
1
-
-
45849115453
-
TRAIL death receptors as tumor suppressors and drug targets
-
Finnberg N, El Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 2008;7:1525-8.
-
(2008)
Cell Cycle
, vol.7
, pp. 1525-1528
-
-
Finnberg, N.1
El Deiry, W.S.2
-
2
-
-
0037273848
-
Apo2L/TRAIL and its death and decoy receptors
-
LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
-
(2003)
Cell Death Differ
, vol.10
, pp. 66-75
-
-
LeBlanc, H.N.1
Ashkenazi, A.2
-
3
-
-
34249663310
-
Targeting death-inducing receptors in cancer therapy
-
Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007;26:3745-57.
-
(2007)
Oncogene
, vol.26
, pp. 3745-3757
-
-
Takeda, K.1
Stagg, J.2
Yagita, H.3
Okumura, K.4
Smyth, M.J.5
-
4
-
-
76749170208
-
Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation
-
Verbrugge I, Maas C, Heijkoop M, Verheij M, Borst J. Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death Differ 2010;17:551-61.
-
(2010)
Cell Death Differ
, vol.17
, pp. 551-561
-
-
Verbrugge, I.1
Maas, C.2
Heijkoop, M.3
Verheij, M.4
Borst, J.5
-
5
-
-
40449134499
-
Tumor necrosis factor: renaissance as a cancer therapeutic
-
Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets 2008;8:124-31.
-
(2008)
Curr Cancer Drug Targets
, vol.8
, pp. 124-131
-
-
Daniel, D.1
Wilson, N.S.2
-
6
-
-
84858423116
-
Systemic use of tumor necrosis factor alpha as an anticancer agent
-
Roberts NJ, Zhou S, Diaz LA, Jr., Holdhoff M. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2011;2:739-51.
-
(2011)
Oncotarget
, vol.2
, pp. 739-751
-
-
Roberts, N.J.1
Zhou, S.2
Diaz Jr., L.A.3
Holdhoff, M.4
-
7
-
-
0033764170
-
Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
-
Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185- 90.
-
(2000)
Nat Biotechnol
, vol.18
, pp. 1185-1190
-
-
Curnis, F.1
Sacchi, A.2
Borgna, L.3
Magni, F.4
Gasparri, A.5
Corti, A.6
-
8
-
-
67649998165
-
Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system
-
(Lond)
-
Goel R, Shah N, Visaria R, Paciotti GF, Bischof JC. Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system. Nanomedicine (Lond) 2009;4:401-10.
-
(2009)
Nanomedicine
, vol.4
, pp. 401-410
-
-
Goel, R.1
Shah, N.2
Visaria, R.3
Paciotti, G.F.4
Bischof, J.C.5
-
9
-
-
0032713075
-
Safety and antitumor activity of recombinant soluble Apo2 ligand
-
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
-
(1999)
J Clin Invest
, vol.104
, pp. 155-162
-
-
Ashkenazi, A.1
Pai, R.C.2
Fong, S.3
Leung, S.4
Lawrence, D.A.5
Marsters, S.A.6
-
10
-
-
0035050960
-
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
-
Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383- 5.
-
(2001)
Nat Med
, vol.7
, pp. 383-385
-
-
Lawrence, D.1
Shahrokh, Z.2
Marsters, S.3
Achilles, K.4
Shih, D.5
Mounho, B.6
-
11
-
-
49049086338
-
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
-
Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-30.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3621-3630
-
-
Ashkenazi, A.1
Holland, P.2
Eckhardt, S.G.3
-
12
-
-
52649109068
-
The TRAIL apoptotic pathway in cancer onset, progression and therapy
-
Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 782-798
-
-
Johnstone, R.W.1
Frew, A.J.2
Smyth, M.J.3
-
14
-
-
72449164087
-
Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells
-
Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res 2009;7:1835- 44.
-
(2009)
Mol Cancer Res
, vol.7
, pp. 1835-1844
-
-
Yoshida, T.1
Zhang, Y.2
Rivera Rosado, L.A.3
Zhang, B.4
-
15
-
-
57749097095
-
TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5
-
Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008;6:1861-71.
-
(2008)
Mol Cancer Res
, vol.6
, pp. 1861-1871
-
-
Zhang, Y.1
Zhang, B.2
-
16
-
-
47749089820
-
Regulation of TNFR1 and CD95 signalling by receptor compartmentalization
-
Schutze S, Tchikov V, Schneider-Brachert W. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol 2008;9:655- 62.
-
(2008)
Nat Rev Mol Cell Biol
, vol.9
, pp. 655-662
-
-
Schutze, S.1
Tchikov, V.2
Schneider-Brachert, W.3
-
17
-
-
19244368330
-
Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells
-
Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, Dimitrov T, et al. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 1998;392:726-30.
-
(1998)
Nature
, vol.392
, pp. 726-730
-
-
Tollefson, A.E.1
Hermiston, T.W.2
Lichtenstein, D.L.3
Colle, C.F.4
Tripp, R.A.5
Dimitrov, T.6
-
18
-
-
4444341939
-
Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles
-
Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S, Held-Feindt J, et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004;21:415-28.
-
(2004)
Immunity
, vol.21
, pp. 415-428
-
-
Schneider-Brachert, W.1
Tchikov, V.2
Neumeyer, J.3
Jakob, M.4
Winoto-Morbach, S.5
Held-Feindt, J.6
-
19
-
-
33644858084
-
The role of receptor internalization in CD95 signaling
-
Lee KH, Feig C, Tchikov V, Schickel R, Hallas C, Schutze S, et al. The role of receptor internalization in CD95 signaling. EMBO J 2006;25:1009-23.
-
(2006)
EMBO J
, vol.25
, pp. 1009-1023
-
-
Lee, K.H.1
Feig, C.2
Tchikov, V.3
Schickel, R.4
Hallas, C.5
Schutze, S.6
-
20
-
-
33745928465
-
Death-receptor activation halts clathrin-dependent endocytosis
-
Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Maziere AM, et al. Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci U S A 2006;103:10283-8.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 10283-10288
-
-
Austin, C.D.1
Lawrence, D.A.2
Peden, A.A.3
Varfolomeev, E.E.4
Totpal, K.5
De Maziere, A.M.6
-
22
-
-
68049125070
-
TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells
-
Zhang Y, Yoshida T, Zhang B. TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells. Cancer Biol Ther 2008;8.
-
(2008)
Cancer Biol Ther
, pp. 8
-
-
Zhang, Y.1
Yoshida, T.2
Zhang, B.3
-
23
-
-
76749110412
-
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies
-
Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010;16:1256-63.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1256-1263
-
-
Camidge, D.R.1
Herbst, R.S.2
Gordon, M.S.3
Eckhardt, S.G.4
Kurzrock, R.5
Durbin, B.6
-
24
-
-
77956414973
-
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer
-
Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;28:2839-46.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2839-2846
-
-
Herbst, R.S.1
Eckhardt, S.G.2
Kurzrock, R.3
Ebbinghaus, S.4
O'Dwyer, P.J.5
Gordon, M.S.6
-
25
-
-
79955995604
-
Drozitumab, a human antibody to death receptor 5, has potent anti-tumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response
-
Kang Z, Chen J, Yu Y, Li B, Sun SY, Zhang B, et al. Drozitumab, a human antibody to death receptor 5, has potent anti-tumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res 2011.
-
(2011)
Clin Cancer Res
-
-
Kang, Z.1
Chen, J.2
Yu, Y.3
Li, B.4
Sun, S.Y.5
Zhang, B.6
-
26
-
-
79952336885
-
Combined modality therapy with TRAIL or agonistic death receptor antibodies
-
Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011;11:431-49.
-
(2011)
Cancer Biol Ther
, vol.11
, pp. 431-449
-
-
Amm, H.M.1
Oliver, P.G.2
Lee, C.H.3
Li, Y.4
Buchsbaum, D.J.5
-
27
-
-
84857862604
-
Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4 T cells and apoptosis
-
Barblu L, Herbeuval JP. Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4 T cells and apoptosis. PLoS One 2012;7:e32874.
-
(2012)
PLoS One
, vol.7
-
-
Barblu, L.1
Herbeuval, J.P.2
-
28
-
-
13844271270
-
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study
-
Reesink-Peters N, Hougardy BM, van den Heuvel FA, ten Hoor KA, Hollema H, Boezen HM, et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 2005;96:705- 13.
-
(2005)
Gynecol Oncol
, vol.96
, pp. 705-713
-
-
Reesink-Peters, N.1
Hougardy, B.M.2
van den Heuvel, F.A.3
ten Hoor, K.A.4
Hollema, H.5
Boezen, H.M.6
-
29
-
-
0000005230
-
Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells
-
Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000;164:3961-70.
-
(2000)
J Immunol
, vol.164
, pp. 3961-3970
-
-
Zhang, X.D.1
Franco, A.V.2
Nguyen, T.3
Gray, C.P.4
Hersey, P.5
-
30
-
-
0042835740
-
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors
-
Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de JS. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003;9:3397-405.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 3397-3405
-
-
Spierings, D.C.1
de Vries, E.G.2
Timens, W.3
Groen, H.J.4
Boezen, H.M.5
de, J.S.6
-
31
-
-
67249100235
-
Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy
-
Leithner K, Stacher E, Wurm R, Ploner F, Quehenberger F, Wohlkoenig C, et al. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer 2009;65:98-104.
-
(2009)
Lung Cancer
, vol.65
, pp. 98-104
-
-
Leithner, K.1
Stacher, E.2
Wurm, R.3
Ploner, F.4
Quehenberger, F.5
Wohlkoenig, C.6
-
32
-
-
83355163382
-
Importin beta1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells
-
Kojima Y, Nakayama M, Nishina T, Nakano H, Koyanagi M, Takeda K, et al. Importin beta1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells. J Biol Chem 2011;286:43383-93.
-
(2011)
J Biol Chem
, vol.286
, pp. 43383-43393
-
-
Kojima, Y.1
Nakayama, M.2
Nishina, T.3
Nakano, H.4
Koyanagi, M.5
Takeda, K.6
-
33
-
-
67349162130
-
Tumour necrosis factor and cancer
-
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 361-371
-
-
Balkwill, F.1
-
34
-
-
2442678063
-
Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor
-
Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004;64:3653-60.
-
(2004)
Cancer Res
, vol.64
, pp. 3653-3660
-
-
Demidenko, Z.N.1
Blagosklonny, M.V.2
-
35
-
-
80053410931
-
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link
-
Fulda S. Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link. Oncotarget 2011;2:418-21.
-
(2011)
Oncotarget
, vol.2
, pp. 418-421
-
-
Fulda, S.1
-
36
-
-
3042800912
-
Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad phosphorylation on Ser-75
-
Zhang B, Zhang Y, Shacter E. Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad phosphorylation on Ser-75. Mol Cell Biol 2004;24:6205-14.
-
(2004)
Mol Cell Biol
, vol.24
, pp. 6205-6214
-
-
Zhang, B.1
Zhang, Y.2
Shacter, E.3
-
37
-
-
34548695886
-
TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma
-
Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:716-23.
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.69
, pp. 716-723
-
-
Sanlioglu, A.D.1
Korcum, A.F.2
Pestereli, E.3
Erdogan, G.4
Karaveli, S.5
Savas, B.6
|